Substituted Benzimidazole Derivatives for IL-17 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological agents fail to effectively modulate IL-17 activity, which is crucial for treating inflammatory and autoimmune disorders, as they do not specifically target the precise structural class of substituted benzimidazole derivatives.
Innovation Solution
Development of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and their analogues, which act as potent modulators of human IL-17 activity, offering a new approach for treating inflammatory and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmacological agents are used to modulate IL-17 activity, then treatment of inflammatory and autoimmune disorders can be attempted, but the agents fail to effectively modulate IL-17 activity due to lack of specific targeting
Solution Approach 1:
The patent applies local quality by specifying precise structural features at particular positions in the benzimidazole molecule (substituents at R1-R7 positions) to achieve selective binding to IL-17 receptors. Each substituent position is optimized independently to enhance affinity and specificity for IL-17A/F, resolving the contradiction between general efficacy and specific targeting.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations) in the benzimidazole structure to optimize IL-17 modulation. By adjusting parameters such as electron-donating/withdrawing groups and steric configurations, the compounds achieve potent and specific IL-17 activity modulation.
2Measurement precision
If substituted fused bicyclic imidazole derivatives are developed, then specific targeting of IL-17 can be achieved, but the development process increases complexity
Solution Approach 1:
The patent segments the complex molecule into functional modules: the core benzimidazole scaffold provides binding affinity, while substituent groups (R1-R7) provide specificity and pharmacological properties. This modular segmentation allows systematic optimization of specificity without proportionally increasing overall structural complexity.
Solution Approach 2:
The benzimidazole core structure serves multiple functions simultaneously: it provides the basic binding interface for IL-17 receptors, accommodates various substituent patterns for optimization, and maintains pharmacological activity across different derivatives. This multi-functionality reduces the need for entirely new molecular classes.
3Adaptability or versatility
If conventional pharmacological agents are used, then treatment approach can be implemented, but they do not specifically target the precise structural class of substituted benzimidazole derivatives
Solution Approach 1:
The patent uses parameter changes to optimize the balance between structural specificity and therapeutic applicability. By adjusting substituent parameters at different positions, the same core structure can target IL-17 while maintaining versatility for different inflammatory and autoimmune conditions, resolving the contradiction between precision and adaptability.
Data Source
AI summary
A series of substituted fused bicyclic imidazole derivatives of formula (I), including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments including inflammatory and autoimmune disorders, wherein i. a. A represents C—R1 or N; B represents C—R2 or N; D represents C—R3 or N; E represents C—R4 or N; Z represents —CH(R5)N(H)CH2R6, —CH(R5)N(H)S(O)2R6, —C(═CR5aR5b)N(H)C(O)R6, —CH(R5)R7, —CH(R5)N(H)R7 or —CH(R5)C(O)N(H)R7; R0 represents hydrogen or C1-6 alkyl.